[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608215":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":29,"locations":37,"responsibleParty":55,"collaborators":18,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":40,"whyStopped":18,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"The First Affiliated Hospital of Air Force Medicial University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Monomethyl Auristatin E (MMAE) \u002F autologous neutrophil biological agents","EXPERIMENTAL","Isolate the patients' autologous neutriphil cells, induce and culture them with Monomethyl Auristatin E (MMAE) in a GMP-compliant laboratory. Prior to the reinfusion of neutrophil biological agents into patients, stereotactic radiotherapy with a dose of 2-6 Gy is administered to pancreatic cancer lesions. The number of neutrophils that were reinfused was 2.0-8.0x10\\^8.",[13],"Combination Product: Monomethyl Auristatin E (MMAE) \u002F autologous neutrophil biological agents",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"COMBINATION_PRODUCT",[9],null,[20,24,27],{"name":21,"affiliation":22,"role":23},"Lin Wang, Doctor of Medicine(M.D.)","The First Affiliated Hospital of Air Force Military Medical University","STUDY_DIRECTOR",{"name":25,"affiliation":22,"role":26},"Liang Jin, Doctor of Medicine(M.D.)","PRINCIPAL_INVESTIGATOR",{"name":28,"affiliation":22,"role":26},"Yong Chen, Doctor of Medicine(M.D.)",[30,35],{"name":25,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","02984775260","18392388395","jinl2013@163.com",{"name":21,"role":31,"phone":32,"phoneExt":36,"email":18},"13709113260",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The First Affiliated Hospital of the PLA Air Force Military Medical University","RECRUITING","Xi’an","Shanxi","710000","China","CN",{"type":47,"coordinates":48},"Point",[49,50],113.52486,35.99785,{"lat":50,"lon":49},[53],{"name":54,"role":31,"phone":33,"phoneExt":32,"email":34},"Liang Jin, M.D.",{"type":26,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Lin Wang","Professor","100608215","early-phase-1-a-single-arm-investigator-initiated-tria-iit-evaluating-the-safety-and-preliminary-efficacy-of-autologous-drug-loaded-neutrophils-neumed-in-patients-with-unresectable-pancreatic-cancer-100608215",false,"NCT07198659","A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer","A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer（NeuMed-uPC）","NeuMed-uPC","Inclusion Criteria:\n\n* 18-70 years\n* Obtain an informed consent form voluntarily signed by the patient themselves\n* patients with Unresectable Pancreatic Cancer confirmed by Histopathology\n* Patients who either: 1) have received standard first-line treatments, proven ineffective or causing intolerable adverse effects; or 2) have not received the standard first-line treatments and voluntarily opt for Autologous Drug-Loaded Neutrophils (NeuMed)-based therapy\n* EOCG score ≤ 2 and expected survival time ≥ 3 months\n* Liver, kidney and bone marrow functions are basically normal\n\nExclusion Criteria:\n\n* Patients who required anti coagulant therapy\n* Patients with active infectious diseases or a history of bone marrow or organ transplantation\n* Patients with autoimmune diseases or autoinflammatory diseases\n* Patients with a history of severe cardiovascular or cerebrovascular diseases or interstitial lung disease or non-infectious pneumonia\n* Patients who have received live vaccines within 30 days prior to enrollment\n* Patients with no response to bone marrow mobilization\n* Other patients deemed unsuitable for enrollment by the investigator","ALL","18 Years","70 Years",{"count":70,"type":71},3,"ESTIMATED","INTERVENTIONAL",[74],"EARLY_PHASE1","The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.",[77],"Unresectable Pancreatic Cancer",[79,77,80],"Autologous Drug-Loaded Neutrophils (NeuMed)","Monomethyl Auristatin E (MMAE)","2025-09-26",{"date":83,"type":84},"2025-09-30","ACTUAL",{"date":86,"type":84},"2025-07-14",{"date":88,"type":71},"2027-07-14",{"name":5,"class":6},1]